The use of a novel FGFR2-targeting peptide for early detection of FGFR2 overexpression in early-onset gastric cancer and esophageal cancer was investigated, resorting to phage display and fluorescence to identify FGFR2 cell surface overexpression, and finding significantly greater binding in esophageal specimens with high-grade dysplasia compared to Barret’s esophagus or normal mucosa, as well as significantly greater binding in specimens of esophageal squamous cell carcinoma and gastric cancer compared to normal mucosa [31]. The gene discussed is FGFR2; the disease is gastric cancer.